chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received form a registered nurse referring to a 22 years old female patient. The patient's medical history, concurrent condition and concomitant therapy were not provided. The patient was vaccinated with hepatitis b vaccine (recombinant)(manufacturer unknown)(strength, dose, frequency, route, lot number and expiration date were unknown) on the following dates: one dose administered on 19-MAY-1994, second dose on 28-JUN-1994 and the final dose on 07-NOV-1994 (product use issue). On an unknown date, the patient had "negative titers" after vaccinated with 3 doses of hepatitis b vaccine (recombinant)(manufacturer unknown). The outcome of negative titers was unknown. The causal relationship between the hepatitis b vaccine (recombinant)(manufacturer unknown) and the event was unknown. Additional information has been requested.
NONE ADDENDUM NOTE 10/24/22 : OCCURRED 10/18/22 PATIENT REQUESTED FIRST DOSE OF COVID VACCINE AND WAS INADVERTENTLY GIVEN A BOOSTER DOSE BY LPN NO COMPLAINTS OFFERED BY THE PATIENT NO TREATMENT ADVISED.
Pt exp crying uncontrollably beginning 8JUN91; Pt OK p/10JUN91;
Headache, chills, body aches, rigors and sweats. Symptoms persisted for about 24 hours after vaccine.
Information has been received from a nurse practitioner concerning a nurse developed Shingles (unspecified time frame) after administering ZOSTAVAX (Oka/Merck) to an unspecified number of patient's over past several months (dates unspecified). The staff nurse developed a facial rash that was evaluated by an unspecified physician and an ophthalmologist. The staff nurse thought the shingles was transmitted from handling and administering the ZOSTAVAX vaccine (Merck) to patients. No other symptoms or treatment reported. The staff nurse's lesions had completed resolved and she had recovered. Additional information has been requested. This is in follow-up to report (s) previously submitted on 9/24/2008. Additional information is not expected.
Varivax vaccine given 8/13/07 @ 11:00 am. 8/14/07 am-arm sore and large red area 2 1/2" circle-warm/hot to touch. itching-swollen taking Benadryl PO 25 mg and cold compress
Horrible pain in the left arm/Slight at first/Pain has continued and gotten worse/Pain is ridiculous; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Horrible pain in the left arm/Slight at first/Pain has continued and gotten worse/Pain is ridiculous) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 041C21A, 028A21A and 029A21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (Horrible pain in the left arm/Slight at first/Pain has continued and gotten worse/Pain is ridiculous). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Adverse event, at an unspecified dose and frequency and NAPROXEN (MOTRIN [NAPROXEN]) for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (Horrible pain in the left arm/Slight at first/Pain has continued and gotten worse/Pain is ridiculous) had not resolved.            Concomitant medication include diabetic medication.   Patient started feeling pain that same night from the shot, but it was slight at first and thought it was normal. However, pain has continued and gotten worse. Patient went to see his doctor last Thursday and doctor pain is from the shot. Doctor told him to take Advil or Motrin, but "it absolutely does nothing". Patient said "Pain is ridiculous, she have it all the time". Patient tried putting ice and heat on his arm, and although it calms pain at first, then it starts again.
myalgia; headaches; no sense of smell; This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (no sense of smell), MYALGIA (myalgia) and HEADACHE (headaches) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Mar-2021, the patient experienced ANOSMIA (no sense of smell). On an unknown date, the patient experienced MYALGIA (myalgia) and HEADACHE (headaches). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, ANOSMIA (no sense of smell), MYALGIA (myalgia) and HEADACHE (headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not provided. Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Non significant follow up appended
AT 109 PM C/O TIGHTENING OF THROAT, EPI X 3 SEPERATED BY 5 MINUTES ADM IM.  BENADRYL 50 MG IM ADMINISTERED ALSO.  EMS TRANSPORTED TO ER AT 1:24 PM.
Shingrix reconstituted with sterile water.; Shingrix was administered after being reconstituted with sterile water; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number BM27F, expiry date 14th November 2022) for prophylaxis.   On 30th August 2021, the patient received the 1st dose of Shingrix. On 30th August 2021, unknown after receiving Shingrix, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The practice manager reported that, the first dose of Shingrix was administered after being reconstituted with sterile water, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The reporter consented to follow up.
I don't have all the information above about the actual shot. We are required to have a flu Shot due to work in a healthcare facility. I have had a bad reaction to this flu shot. my left arm has had a lump in it for days now. It has swollen much more than normal with pain and swelling around the injection site and up into my neck and shoulder resulting in pain and stiffness in my neck making it difficult to move my neck. The swelling spread up through my arm shoulder and neck in a way that it was noticeable to my husband and coworker that my shoulder and neck were very knotted up and swollen. This is just a much more exaggerated response than I have had to any other shot. I also noticed that my left eye was bothering me as well but that is harder to define just kind of weepy and a little blurry it took me a while to realize that was all connected and started right at the injection site.
Started to itch yesterday, and today I realized that its getting swollen, developing like a hive, randomly sting, its hot at touch
Arm started swelling and turning red approximately 4 days after vaccine administration. Ran low grade fever to as high as 104 degrees. I saw her on 10/8/10 and at that time her left arm had softball diameter sized hard, red, raised area surrounding scabbed immunization site. There was redness from top of shoulder to her elbow with blister-like lesions going to back. Lymph nodes in neck and axilla very enlarged. Had difficulty turning neck due to swelling. Negative kernig. CBC showed white count of 9.3. She was also seen on 10/9/10 and 10/12/10 for severe headache and was sent to the Medical Center. I did not see her for the last 2 appointments.
his 2nd Pfizer COVID19 vaccine today and is asking if it would be okay for him to get vaccinated today after being cleared from quarantine last Saturday because he had COVID; his 2nd Pfizer COVID19 vaccine today and is asking if it would be okay for him to get vaccinated today after being cleared from quarantine last Saturday because he had COVID; This is a spontaneous report from a Pfizer-sponsored program  via medical information team. A contactable consumer (patient) reported that a male patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; formulation: Solution for injection, Lot Number: unknown), via an unspecified route of administration on an unspecified date at a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. On an unknown date patient was diagnosed with COVID and he was enquiring that he was scheduled for his 2nd Pfizer COVID19 vaccine today and was asking if it would be okay for him to get vaccinated today after being cleared from quarantine last Saturday. Outcome for the events was unknown.  Information on the lot/batch number has been requested.
Received call from Urgent Care, child was clinically diagnosed with chickenpox. Received H&P noted fever, sore throat, malaise, crying and vesicular rash noted by clinician. Called child's mother with translator and rash stared on 6/29/19 in face, trunk and arms about 35 lesions that day. More at this time (07/05/19) per  mother , child is better most of the lesions are crusting. Mother states not sure how many lesion too many to count maybe 150-200 and still running low grade fever.
Approx 2-3 days after receiving standard 4 month vaccinations patient stopped babbling/baby talk completely and started grunting.  The grunting got progressively worse occurring in bursts of 15-30 seconds every 1-2 minutes she was awake.  Patient had previously been very interactive and talkative.  The reaction got progressively worse for 1-1.5wks then subsided and her talking was back.
No known adverse effects.; a 64 year old patient received a dose of PROQUAD; Information has been received from a administrator referring to a 64 years old patient of unknown gender. Information of concomitant therapy, pertinent medical history and drug reactions/allergies was not reported.  On 08-MAY-2019, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (1 dosage form, strength, frequency, lot#, therapy type and expiration date were unknown) subcutaneously for prophylaxis (inappropriate age at vaccine administration).  No known adverse effects.
caller reports no additionalat time of call; dose of VARlVAX with the labeled expiry 10/14/2021 was administered to a patient on 11/22/2021; This spontaneous report was received from a licensed practical nurse and refers to a 20-year-old patient of unknown age. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  On 22-NOV-2021, the patient was vaccinated with an expired dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliter, lot # S032352, expiration date 14-OCT-2021 (route of administration and anatomical location were not provided) for prophylaxis. No additional adverse event was reported.
Headache - took Tylenol, ongoing  Burning all over body - took Benadryl, resolved  Dizziness - rest Cough
Information has been received from a registered nurse concerning a male who on 01/05/99 was vaccinated with Varivax. In 01/02, the child developed chickenpox. It was reported that the child developed 15 lesions. Medical attention was sought. At the time of this report, the outcome of the event was unknown. No further information was available.
Patient experienced extreme nausea and vomiting and became dehydrated and had to go to urgent care. She also is experiencing mouth sores.
Gland on the left side of the neck near the jaw became swollen; tenderness at injection site; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Gland on the left side of the neck near the jaw became swollen) and VACCINATION SITE PAIN (tenderness at injection site) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026720A) for COVID-19 vaccination.     The patient's past medical history included Swollen glands.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced LYMPHADENOPATHY (Gland on the left side of the neck near the jaw became swollen) and VACCINATION SITE PAIN (tenderness at injection site). At the time of the report, LYMPHADENOPATHY (Gland on the left side of the neck near the jaw became swollen) and VACCINATION SITE PAIN (tenderness at injection site) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's concomitant medications weren't reported Treatment information was not provided   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: Follow up information included outcome of the events.
Information regarding Flumist (2003-2004 Formula)(influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a healthcare professional regarding a female pt who experienced upper respiratory infection, general sinus infection and fever.  The pt received the first dose in Dec 2003.  Relevant medical history was not provided.  Indication for Flumist (2003-2004 Formula) was immunization.  Product was administered in Dec 2003. Dose regimen was 0.5mL (IN).  Concomitant medications were not reported.  The pt received Flumist on an unspecified date in the beginning of December 2003.  She has been experiencing an upper respiratory infection (upper respiratory tract infection) and general sinus infection (sinusitis) every 2 weeks.  No additional information was available at the time of this report.
A few days after the vaccination my father had a sore throat and slight cough.  This progressed into pneumonia like symptoms and he died on 2/11/21.
Information has been received from a physician concerning an approximately 60 year old patient who in approximately Oct 2002, was vaccinated in the arm with a dose of pneumococcal vaccine 23 polyvalent (lot# 642722/0165M). Concomitant therapy, that same day, included a dose of influenza virus vaccine in the opposite arm. Within hours of vaccination, in approximately Oct 2002, the patient developed a "big time reaction" from the deltoid to the elbow. The reaction persisted for 3 to 5 days. The patient received palliative treatment. The physician reported that the patient had priori vaccination with pneumococcal vaccine 23 polyvalent over 5 years ago. The reporter expressed a concern with the lot. The records of testing prior to release of this lot have been checked by compliance and found to be satisfactory. The lot complies with the standards of the evaluation and research and was released. The patient sought unspecified medical attention. Additional information has been requested.
Severe diarrhea for over four weeks 7-9 times per day, cries out in stomach pain. Started infant on probiotics once per day. No further doses of Rotateq.
Fever of 101.6; Headache; Fatigue; A spontaneous report () was received from a consumer concerning a 60 years old  patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events fever of 101.6/pyrexia, headache and fatigue.  The patient's medical history was not provided. Concomitant medications reported were mometasone furoate, omeprazole, metformin, rosuvastatin calcium, acetylsalicylic acid, atenolol.  The patient received first of two planned doses of mRNA-1273 (lot/batch: Unknown) on an unknown date.  On 23 Jan 2021, prior to the onset of the events the patient received their second of two planned doses of mRNA-1273 (lot/batch: Unknown) intramuscularly for prophylaxis of COVID-19 infection.  On an unknown date in 2021, the patient experienced the events Fever of 101.6, Headache, Fatigue.  Treatment details included Antibiotics.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events, fever of 101, 6, headache, fatigue was unknown.
Experienced gripping chest pain, a sharp pain when breathing. Had to sit and rest for 1 hour continued to rest the after noon. Today feels fine.
Only adverse event is that scab is extremely small -- 5 mm. Previously vaccinated with good take.
Respiratory distress and facial swelling.  Treated with epinephrine and albuterol in office.  Admitted to hospital for observation due to unstable living situation. DC DX: Anaphyllaxis. Admitted for respiratory distress. History of asthma. Experienced wheezing, puffiness around eye area and difficulty breathing withing 10 minutes after vaccination.
pt recv vax 28OCT97 & 8NOV97 11 days p/vax pt broke out w/full blown chickenpox w/more than 100 lesions;
6/23/04-1PM tetanus given, 6/24/04 1AM N/V x 1, body aches, 102 fever; 6/25/04 sx improving, no treatment, hydration.
At 8 pm patient began to cough and vomit, throughout he night 12:30am, he began with chills and fever and complaing his feet are "tingling". He also is unable to move in upwards where the vaccine was given.
COVID-19 infection symptoms started on 01/13/2023 in the morning. I had sinus symptoms and I thought I was having sinus. I had fever and headache. I took over the counter medication cold medication but it didn't help much. On 01/15/2023 I went to the urgent care and after testing me they informed me that I had COVID-19 infection. They advised me to take medication for COVID-19 but because I take a heart medication I decided not to take. I took nebulizer I had from before and MUCINEX as per needed.
Information has been received from a nurse practitioner concerning a 17 year old male with a mold allergy who on the afternoon of 01/29/2001 was vaccianted IM with a dose of hep B vaccine recombinant. There was no concomitant medication. At approx. 3am on 01/30/2001 the pt experienced abdominal cramping, diarrhea and chills. He did not have an elevated temp. The pt stayed home from school that day and experienced chills all day. It was reported that the symptoms lasted for 24 hours. He felt well the next day and returned to school. Unspecified medical attention was sought. Additional info is not expected.
Patient was given a 3rd dose by mistake.  No adverse reaction was noted and patient is doing fine.
developed pain at the injection site; swelling at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (developed pain at the injection site) and VACCINATION SITE SWELLING (swelling at the injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, the patient experienced VACCINATION SITE PAIN (developed pain at the injection site) and VACCINATION SITE SWELLING (swelling at the injection site). At the time of the report, VACCINATION SITE PAIN (developed pain at the injection site) and VACCINATION SITE SWELLING (swelling at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
It did not help me/Suspected vaccination failure; It did not help me; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination  failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient got the Shingles vaccine and it did not help him/her. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure since the details regarding completion of primary immunization schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. Note: The case was kept conservatively valid
suspected vaccination failure; after shot, shingles; This case was reported by a consumer via  interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The patient got shingles on face and had intermittently since then, but worse than as that of reporter. This case was considered as suspected vaccination failure, since the details regarding the completion of the primary immunization and laboratory confirmation of shingles were not provided. This case had been linked with case US2021AMR224902, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR224902:Same reporter
Patient has large area (10-11 centimeter) of redness and swelling at site.  Small vesicle at needle site.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 71-year-old male patient received BNT162b2 (BNT162B2), on 22Sep2022 at 01:00 as dose 2, single (Lot number: BVGJ6739) at the age of 70 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Nov2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive; Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19 took Paxlovid from 24Nov2022 to 29Nov2022.  Clinical course: The patient has no known allergies.
Swelling redness (2? diameter) sore to touch and localized itching at injection site